110
Participants
Start Date
March 11, 2020
Primary Completion Date
July 26, 2023
Study Completion Date
November 27, 2023
BI 905711
BI 905711
Brussels - UNIV Saint-Luc, Brussels
UZ Leuven, Leuven
Memorial Sloan-Kettering Cancer Center, New York
HOP Jean Minjoz, Besançon
Hospital Ramón y Cajal, Madrid
CTR Eugène Marquis, Rennes
Hospital Clínico de Valencia, Valencia
Universitätsklinikum Mannheim GmbH, Mannheim
CTR Leon Berard, Lyon
The University of Texas MD Anderson Cancer Center, Houston
START South Texas Accelerated Research Therapeutics, LLC, San Antonio
HOP la Milétrie, Poitiers
Beijing Cancer Hospital, Beijing
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou
Yale Cancer Center, New Haven
National Cancer Center Hospital East, Chiba, Kashiwa
Korea University Anam Hospital, Seoul
Hospital Vall d'Hebron, Barcelona
Lead Sponsor
Boehringer Ingelheim
INDUSTRY